International Journal of Molecular Sciences · 2020 · 17 citations · 34 references
MedicineOncologyPathologyCancer ImmunologyMolecular OncologyNeoplasiaCancer Molecular PathologyImmune Checkpoint RegulationImmuno-oncology BiomarkersMalignant NeoplasmsSquamous Cell CarcinomaTumor-associated AntigensClinicopathological CorrelationImmune Checkpoint BiomarkersImmune Checkpoint Ligand ExpressionLocal Recurrence DetectionLocal Tumor RecurrenceMolecular Recurrence MarkersPrognostic Biomarker DiscoveryRecurrence-free Survival
Head and neck squamous cell carcinoma (HNSCC)is the 6th most common cancer in humans worldwide and is associated with a poor prognosis for patients. NR2F6 has been identified as an immune checkpoint molecule in tumor-infiltrating T lymphocytes and is associated with a poor prognostic outcome in various cancers. The prognostic value of NR2F6 in HNSCC has not been described yet. We used a large, representative and clinically well-characterized cohort of 383 HNSCC patients, of which 22.4% developed a local recurrence. The NR2F6 expression was analyzed by using immunohistochemistry and was afterward correlated with clinical characteristics and clinicopathological features of HNSCC patients. Primary tumors from patients who develop a local recurrence have a higher NR2F6 expression than primary tumors which do not develop a local recurrence. Furthermore, a high NR2F6 expression is associated with poorer recurrence-free survival, although there is no correlation with overall survival. NR2F6 expression is independent of the T stage and UICC stage. NR2F6 might be a new prognostic biomarker for the early detection of local recurrences in HNSCC patients. Therefore, it may help to improve the recognition of patients who would benefit from more frequent follow-up examinations.
34
T. Tong, S. Bolden, Phyllis A. Wingo · CA A Cancer Journal for Clinicians · 1996 · 1.8K citations · Full text
Medicine, Biostatistics, Oncology +17
Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco et al. · Journal for ImmunoTherapy of Cancer · 2019 · 738 citations · Full text
Medicine, Immunology, Oncology +13
Importance of Comorbidity in Head and Neck Cancer
Jay F. Piccirillo · The Laryngoscope · 2000 · 401 citations